PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2058392
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2058392
Non-Invasive Biosensor Market is estimated to be valued at USD 7.5 Bn in 2026 and is expected to reach USD 16.7 Bn by 2033, growing at a compound annual growth rate (CAGR) of 12.5% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 7.5 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 12.50% | 2033 Value Projection: | USD 16.7 Bn |
Non-invasive biosensors are novel diagnosis devices, which do not require any invasive procedure for detection of any substance or disease. This technology uses sweat, tears, or saliva for diagnostic purpose. Glucose monitoring and blood analytes monitor have become available in the market, which uses non-invasive biosensors. Moreover, there are many non-invasive biosensors under development and under clinical trial for new applications such as cancer and blood alcohol concentration detection.
Increasing approval and launches of novel non-invasive biosensors is expected to boost growth of global non-invasive biosensors market in the near future. For instance, in 2016, Nemaura Medical, Inc. received CE approval in the European Union for its latest sugarBEAT, a minimally invasive wireless continuous glucose monitor. Moreover, in 2013, Integrity Applications Inc. received CE marking for its new GlucoTrack DF-F device, a non-invasive blood glucose monitoring device. Increasing research and development activities for developing novel non-invasive biosensors is also expected to drive growth of market in the near future. For instance, in 2017, Mclean Hospital announced that LabPatch-alcohol, its non-invasive skin patch that detects blood alcohol concentration, is in clinical trial. LabPatch-alcohol is in early Phase 1 stage of clinical trial. Furthermore, increasing prevalence of diabetes is also expected to increase demand for non-invasive biosensors for diagnosis. According to the World Health Organization (WHO), 2014, around 8.5% of adults aged 18 and above accounting for 422 million adults were suffering from diabetes worldwide.